Gustave Roussy, Cancer Campus, Grand Paris

🇫🇷France

Country: 🇫🇷France

Ownership: Private

Employees: -

Market Cap: -

Website

Clinical Trials

Trial of a Vaccination With Tumor Antigen-loaded Dendritic Cell-derived Exosomes

Phase 2

Completed

Conditions: Non Small Cell Lung Cancer

First Posted Date: 2010-07-09

Last Posted Date: 2018-03-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 41

Registration Number: NCT01159288

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Evaluation of the Diagnostic Performance of MRI±Biopsy to Optimize Resection of Ductal Carcinoma In Situ (DCIS) Breast Cancer

Phase 3

Completed

Conditions: Breast Cancer

Interventions: Procedure: MRI±biopsy

First Posted Date: 2010-04-28

Last Posted Date: 2016-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 360

Registration Number: NCT01112254

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Study Comparing Isolated Pelvic Perfusion With TNF-α 0.3 mg and Melphalan 1.5 mg/kg Versus Standard Treatment in Patients With Non Resectable, Recurrent Gynaecologic or Digestive Pelvic Cancer

Phase 3

Completed

Conditions: Gynaecologic or Digestive Pelvic Cancer

Interventions: Drug: Isolated pelvis perfusion
Radiation: radiotherapy
Procedure: Surgery

First Posted Date: 2009-07-30

Last Posted Date: 2015-03-12

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 101

Registration Number: NCT00949039

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Double-blind, Placebo-controlled, Randomized Study of the Effectiveness of Escitalopram on Emotional Distress of Head and Neck Cancer Patients During Cancer Treatment

Phase 3

Conditions: Carcinomas

Interventions: Drug: Escitalopram

First Posted Date: 2009-07-09

Last Posted Date: 2009-09-02

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 100

Registration Number: NCT00935675

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Treatment of High-Risk Cerebral Primitive Neuroectodermal Tumors in Children Aged Over 5 Years

Phase 2

Completed

Conditions: Metastatic, Cerebral Primitive Neuroectodermal Tumors

Interventions: Drug: Chemotherapy (carboplatin, etoposide, thiotepa)

First Posted Date: 2009-07-09

Last Posted Date: 2020-06-29

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 68

Registration Number: NCT00936156

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Studies of Temozolomide in Combination With Topotecan in Refractory and Relapsed Paediatric Solid Tumours

Phase 2

Completed

Conditions: Solid Tumors
Brain Tumors
Neuroblastoma

Interventions: Drug: Temozolomide/Hycamtin (Topotecan)

First Posted Date: 2009-06-11

Last Posted Date: 2016-01-26

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 129

Registration Number: NCT00918320

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Sorafenib and Temozolomide in Treating Patients With Stage III or Stage IV Melanoma

Phase 1

Conditions: Melanoma (Skin)

First Posted Date: 2008-12-19

Last Posted Date: 2010-10-07

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 58

Registration Number: NCT00811759

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Cidofovir in Treating Patients With Stage IB, Stage II, Stage III, or Stage IVA Cervical Cancer Who Are Receiving Chemotherapy and Radiation Therapy

Phase 1

Conditions: Cervical Cancer
Precancerous Condition

First Posted Date: 2008-12-19

Last Posted Date: 2010-01-28

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 24

Registration Number: NCT00811408

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Biliary Cancers: EGFR INhibitor, Gemcitabine and Oxaliplatin

Phase 2

Completed

Conditions: Advanced Biliary Cancer

Interventions: Drug: Gemox, Cetuximab

First Posted Date: 2007-11-01

Last Posted Date: 2012-06-13

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 150

Registration Number: NCT00552149

Locations: 🇫🇷
Institut Gustave Roussy, Villejuif, France

Leucovorin, Fluorouracil, Cetuximab, and Oxaliplatin in Treating Patients With Stage IV Colorectal Cancer and Liver Metastases That Cannot Be Removed by Surgery

Phase 2

Completed

Conditions: Colorectal Cancer
Metastatic Cancer

First Posted Date: 2007-10-16

Last Posted Date: 2011-05-17

Lead Sponsor: Gustave Roussy, Cancer Campus, Grand Paris

Target Recruit Count: 45

Registration Number: NCT00544349

Locations: 🇫🇷
Centre Eugene Marquis, Rennes, France
🇫🇷
Centre de Lutte Contre le Cancer Georges-Francois Leclerc, Dijon, France
🇫🇷
Centre Regional Francois Baclesse, Caen, France

and more 4 locations

© Copyright 2024. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy